It is nowwell knownthat symptomssuch as arterial and venous thrombosis, recurrent fetal loss, central nervous system involvement and thrombocytopenia in patients with systemic lupus erythematosus (SLE) are associated with the presence of antiphospholipid antibodies. In addition, antiphospholipid antibodies can be found in patients with no other apparent autoimmune diseases and maycause cerebral infarction, myocardial infarction and other thromboembolitic complications.
The term "antiphospholipid syndrome" (APS) is given to these conditions.
Many studies have established the importance of anticardiolipin antibody (aCL) for predicting thrombotic symptoms and fetal loss in patients with SLE. More recent studies have shown that binding to cardiolipin of IgG class aCL found in patients with APSis dependent on the existence ofa co factor, namely p2-glycoprotein I (P2-GPI). The issue concerning the antigenic specificities of aCL is currently being studied by numerous laboratories.
Pulmonary hypertension (PH) is one of the most life threatening complications of collagen diseases including systemic sclerosis, mixed connective tissue disease and SLE. In particular, PH in SLE often resembles the primary idiopathic type of PH, that is with clear lung fields and no apparent evidence of pulmonary thromboembolism. Occurrence of PH in SLE patients is considered uncommon, but one study suggests that this condition may be present in 14% of SLE patients (1) . Although its pathogenesis is not clearly understood to date, abnormal vasospasm, platelet abnormalities, immunecomplex deposition in pulmonary vessels and defective fibrinolysis have been suggested as possible pathogenic factors. The association of antiphospholipid antibodies and PH is beginning to draw attention of many rheumatologists. This association in SLE patients was originally described by Asherson et al (2) . In their series of 6 SLEpatients with PH, 5 were positive for lupus anticoagulant activity. It is of interest that, oftheirpatients, 3 were positive for Raynaud' s phenomenon, suggesting that abnormal vasospasm mayalso have contributed to the occurrence of PHin these patients. It is also of importance that PHhas been reported to occur in patients with primary APS(3). Primary APS patients present with various thrombotic episodes without apparent underlying autoimmune diseases. Furthermore, a high incidence of antiphospholipid antibodies in patients diagnosed as "primary idiopathic" PH has been reported (4) . Therefore, the presence of antiphospholipid antibodies should be considered in patients with primary PH.
In this issue ofInternalMedicine, Yutani et al describe a case of SLE presenting with severe PH (5). The patient died despite aggressive treatment, and postmortem examination revealed fresh and organized thromboemboli in many of the small arteries. These small thrombi were thought to be the cause of PH in this patient. This condition should always be considered as a cause of PHin collagen disease patients, since this maybe easily overlooked clinically. Finally, it should be emphasized that PH or pulmonary embolism may be present in patients with primary or secondary APS,whodo not showany respiratory symptomssuch as dyspnea or chest pain. Whena patient is diagnosed as having
